Development of chemotherapeutics for unresectable advanced esophageal cancer.

Development of chemotherapeutics for unresectable advanced esophageal cancer. Expert Rev Anticancer Ther. 2020 Aug 21;: Authors: Imazeki H, Kato K Abstract INTRODUCTION: The prognosis of unresectable advanced esophageal squamous cell carcinoma (ESCC) has gradually improved due to efforts for the development of systemic chemotherapy or concurrent chemoradiotherapy. Areas covered: Chemotherapeutic agents such as cytotoxic agents, molecular-targeted agents, and immune checkpoint inhibitors, sometimes used with irradiation, lead in the treatment of unresectable advanced ESCC. Here, we review the latest treatment strategies for unresectable advanced ESCC and discuss future perspectives. Expert opinion: Immunotherapeutic agents will be part of the treatment of unresectable advanced ESCC in the near future. However, definitive predictive biomarkers to determine good patient candidates remain unclear for immunotherapy in patients with ESCC. Further research is warranted to identify those biomarkers working individually and in combination. Moreover, genome-based therapeutics enable individualized and patient-specific treatment. The development of molecular-targeted drugs against actionable or druggable genes is in progress. PMID: 32820965 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Related Links:

Authors: Peng C, Cohen DJ Abstract INTRODUCTION: Esophageal squamous cancer remains an important cause of mortality worldwide with two new immunotherapy drugs recently approved for metastatic disease. AREAS COVERED: The authors review the epidemiology and genomics of esophageal squamous cell carcinoma. They also examine prior trials involving targeted agents under investigation as well immunotherapies that have been approved and novel combinations. EXPERT OPINION: Great advances have been made in characterizing the molecular changes in esophageal carcinoma. However, relatively few drugs have shown benefit i...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
moto Approximately 604,000 new cases of esophageal cancers (EC) are expected to be diagnosed in 2020, resulting in 537,000 cancer deaths worldwide. (...)
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusions: This study demonstrated that definitive radiotherapy using 3DCRT and IMRT provides promising outcomes for locally advanced ESCC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsypTNM stage grouping in the AJCC 8th edition provided a better predictive performance for DSS and OS than that in the 7th edition. ypStage in the 8th edition was the most reliable prognostic factor for ESCC patients who underwent surgery after neoadjuvant CF therapy.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Nariman-Saleh-Fam Z, Mansoori Y, Saadatian Z, Tavakkoly-Bazzaz J, Daraei A, Zununi Vahed S, Mahmoodzadeh H, Bastami M Abstract Esophageal cancer is one of the least studied aggressive tumors, with the squamous cell carcinoma (ESCC) being the most frequent histological type around the world. Growing evidence has shown that the abnormal expression of microRNAs (miRNAs) in peripheral blood mononuclear cells (PBMCs) is closely related to the pathogenesis of cancers. MiR-146a is a crucial regulator of inflammatory cascades. There is currently no data available regarding the possible role of miR-146a in PBMCs of...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Objective: Esophageal squamous cell carcinoma (ESCC) is one of the most commonly diagnosed cancer types in China. Recent genomic sequencing analysis indicated the over-activation of Hippo/YAP signaling might play important roles for the carcinogenic process and progression for ESCC patients. However, little is known about the molecular mechanisms that controls Hippo signaling activity in ESCC. Our previous studies indicated that PLCE1-an important risk factor for ESCC-linked to ESCC progression through snail signaling, during this period, we found PARK2 was an important downstream target of PLCE1-snail axis. PARK2 was decr...
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Authors: Chen L, Zhang M, Guo M Abstract Esophageal cancer is one of the most common malignancies worldwide. DNA N6-methyladenine (6mA) has been well-studied in prokaryotes, while the distribution and biological functions of DNA 6mA in eukaryotic cells remain to be elucidated. Recently, DNA 6mA epigenetic modification was found in human gastric and liver cancers. To explore the status of DNA 6mA epigenetic modification in esophageal cancer, 101 cases of human esophageal squamous cell carcinoma (ESCC) and matched adjacent normal tissue samples were analyzed by dot blot assay. The levels of genomic DNA 6mA were signi...
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
ConclusionNutritional support provided by an amino acid-rich elemental diet was ineffective for reducing the incidence of adverse events caused by DCF chemotherapy in patients with esophageal cancer.
Source: Esophagus - Category: Gastroenterology Source Type: research
Rationale: Late-onset anastomotic leak (AL) is an uncommon but potentially lethal complication after esophagectomy. Patient concerns: A 74-year-old male patient was readmitted due to chest distress and chills about 3 months after initial esophagectomy for cancer. Diagnoses: The previous endoscopic biopsy revealed primary esophageal squamous cell carcinoma, and sweet esophagectomy with gastric conduit reconstruction was therefore performed. The patient developed AL 3 months after the surgery. Interventions: Naso-leakage extraluminal drainage tube was utilized because the symptoms of the patient were aggravated 1 ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Genetics | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma